CyFlow™ CD25 Purified

CyFlow™ CD25 Purified
Target Species: Human
Antigen: CD25
Field of Interest: Immunophenotyping
Clone: MEM-140
Regulatory Status: RUO
Alternative Name: IL-2R, p55, TAC
Application: Flow cytometry, Immunoprecipitation
Format/Fluorochrome: Purified
Species of Origin: Mouse
Clonality: monoclonal
Isotype: IgM
Product number: AM917650

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA VI—WS Code C C-54 Concentration Unit mg/mL Concentration 1... more
CyFlow™ CD25 Purified
HLDA WorkshopHLDA VI—WS Code C C-54
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
ImmunogenPHA-activated peripheral blood leucocytes
SpecifityThe mouse monoclonal antibody MEM-140 recognizes CD25 antigen, a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.
Background InformationCD25 (IL2Rα, Tac) is a ligand-binding α subunit of interleukin 2 receptor (IL2R). Together with β and γ subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.
Storage BufferThe reagent is provided in Tris buffered saline (TBS) solution, pH ≈8.0, containing 0.1% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T‑lymphocytes in vitro. Pathology. 1991·Jul; 23(3):224‑8. <·PMID:·1838146·> | Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin‑2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res·Immunol. 1992·Jan; 143(1):33‑7. <·PMID:·1565844·> | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·> | Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann·Rheum·Dis. 2000·Nov; 59(Suppl 1):i109‑14. <·PMID:·11053100·> | Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am·J·Surg·Pathol. 2004·Oct; 28(10):1319‑25. <·PMID:·15371947·>

Article successfully added.